While TR 82 is groundbreaking, it has limitations:
This "masking" is typically a time- and temperature-dependent process driven by specific formulation components, most notably the combination of and chelating agents (like citrate or phosphate buffers). These components cause the endotoxin lipopolysaccharides (LPS) to form macromolecular complexes that the LAL reagents cannot recognize, leading to potentially false-negative results. Core Components of TR 82 pda technical report 82
By following these recommendations, organizations can ensure compliance with regulatory requirements, contribute to patient safety, and maintain industry best practices in sterile compounding. While TR 82 is groundbreaking, it has limitations:
: It provides strategies to overcome masking, such as sample demasking or using alternative detection methods like the Monocyte Activation Test (MAT) or recombinant Factor C (rFC). : It provides strategies to overcome masking, such
The report demystifies a complex colloidal phenomenon and provides a practical, risk-based framework to protect patients from masked endotoxin. It acknowledges that no test is perfect, but through aggressive investigation and mitigation, we can close the safety gap.
TR-82 identifies several factors that cause endotoxin to become non-detectable without being destroyed: